Suprachoroidal Injection in the Treatment of Diabetic Macular Edema: Mechanisms, Clinical Advances, and Future Perspectives - Takeaways - MDSpire

Suprachoroidal Injection in the Treatment of Diabetic Macular Edema: Mechanisms, Clinical Advances, and Future Perspectives

  • By

  • Chen, Menghan

  • Jiao, Wanzhen

  • Liu, Tianwei

  • Zhao, Bojun

  • April 16, 2026

  • 0 min

Share

  • 1

    Diabetic macular edema (DME) is a leading cause of visual impairment in diabetes patients.

  • 2

    Traditional treatments for DME often require repeated intravitreal injections, posing risks of complications.

  • 3

    Suprachoroidal space (SCS) injection is an innovative drug delivery method targeting the eye effectively.

  • 4

    SCS injection of triamcinolone acetonide significantly improves vision and reduces macular edema in DME patients.

  • 5

    The review highlights the benefits of SCS injection and its potential to enhance DME management strategies.

Original Source(s)

Suprachoroidal Injection in the Treatment of Diabetic Macular Edema: Mechanisms, Clinical Advances, and Future Perspectives

  • by Chen, Menghan , Jiao, Wanzhen , Liu, Tianwei , Zhao, Bojun

  • April 16, 2026

Related Content

Why Glaucoma Prevalence Is Rising

... and what the eye care community must do next

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

Assessing Temporal Changes in Retinal Non-Perfusion Using Ultra-Widefield Fluorescein Angiography After Intravitreal Therapy for Diabetic Retinopathy